表紙
市場調査レポート

アジア太平洋地域における無侵襲的出生前遺伝学的検査(NIPT)市場

Emerging NIPT Market in Asia Pacific

発行 RNCOS E-Services Pvt. Ltd. 商品コード 290009
出版日 ページ情報 英文 50 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
アジア太平洋地域における無侵襲的出生前遺伝学的検査(NIPT)市場 Emerging NIPT Market in Asia Pacific
出版日: 2013年11月01日 ページ情報: 英文 50 Pages
概要

無侵襲的出生前遺伝学的検査(NIPT)は、分子診断市場において急成長を遂げました。米国で最初に始まったこの検査は、2012年〜2017年のCAGRで49%の成長が見込まれています。最大の成長促進要因は、リスクの高い妊婦に広く受け入れられたことです。この検査におけるダウン症の検出感度は99%以上で、侵襲的出生前検診に伴うリスクを完全に取り除きます。

当レポートでは、アジア太平洋地域におけるNIPT市場について調査分析し、主要国の市場の見通しを提供して、概略以下の構成でお届けいたします。

第1章 アナリストの見解

第2章 調査手法

第3章 イントロダクション

第4章 アジア太平洋地域におけるNIPT市場の見通し

  • オーストラリア
    • 市場の潜在性
    • 市場の概要
    • 規制のシナリオ
  • 中国
    • 市場の潜在性
    • 市場の概要
    • 規制のシナリオ
  • 日本
    • 市場の潜在性
    • 市場の概要
    • 規制のシナリオ
  • インド
    • 市場の潜在性
    • 市場の概要
    • 規制のシナリオ

図表

目次

Non-Invasive Prenatal Testing (NIPT) has catapulted the growth in the molecular diagnostics market. In the US, where the test was initially launched, the market is expected to grow at a CAGR of 49% during 2012-2017. This growth can be attributed to several factors, foremost of all being its high acceptance amongst high-risk pregnant mothers. The tests have a more than 99% sensitivity of detecting Down's syndrome and completely eliminate the risk associated with invasive prenatal tests like CVS and Amniocentesis, gaining them instant popularity amongst the consumers.

But due to a restrictive potential population base in the US, which is estimated at around 700,000, players based in the region were quick to expand beyond their base and launch the tests in the EU and selective regions of Asia-Pacific (APAC). For our study, we have selected the APAC region since it represents a highly underpenetrated market with immense potential for growth.

APAC houses almost a third of global population. According to our report, “Emerging NIPT Market in Asia Pacific” there are around 1 Million potential patients in the region representing a greater than US$ 1 Billion market. The major market in this region lies in Japan, where the rapidly ageing population has created a huge, untapped potential market for players. China is another major region where two local players; BGI and Berry Genomics are expected to collectively accession around 100,000 tests in 2013 alone.

The report covers exhaustive analysis of the potential population for NIPT tests in each region. Different scenarios have been explored in line with the regulatory environment in a given region. Detailed description of current market scenario highlighting the currently available tests, business model followed by players, cost of their tests, number of tests accessioned by them etc. has also been provided.

Besides, test volumes and markets till 2018 have been forecasted. The forecast is conducted on the basis of co-relation and judgmental analysis, which is carried out after carefully studying key factors including rise in penetration, expansion in distributor network, rising popularity and awareness amongst consumers, regulatory scenario and various other drivers and challenges.

Overall, the report presents optimum information and transparent research outlook that highlights opportunities and potentials in the nascent APAC NIPT sector.

Table of Contents

1. Analyst View

2. Research Methodology

3. Introduction

  • 3.1. MaterniT21 PLUS
  • 3.2. Verifi
  • 3.3. Panorama
  • 3.4. Harmony
  • 3.5. NIFTY
  • 3.6. Bambni
  • 3.7. Association of Down's syndrome Risk to Fetus with Mother's Age

4. Asia-Pacific NIPT Market Outlook to 2018

  • 4.1. Australia
    • 4.1.1. Market Potential
    • 4.1.2. Market Overview
    • 4.1.3. Regulatory Scenario
  • 4.2. China
    • 4.2.1. Market Potential
    • 4.2.2. Market Overview
    • 4.2.3. Regulatory Scenario
  • 4.3. Japan
    • 4.3.1. Market Potential
    • 4.3.2. Market Overview
    • 4.3.3. Regulatory Scenario
  • 4.4. India
    • 4.4.1. Market Potential
    • 4.4.2. Regulatory Scenario

List of Figures:

  • Figure 4-1: Australia - Number of Births (‘000), 2013-2018
  • Figure 4-2: Australia - Number of Births by Mother's Risk of Down's syndrome (%), 2011
  • Figure 4-3: Australia - Potential Market in Three Different Scenarios (US$), 2013
  • Figure 4-4: Australia - NIPT Market (Million US$), 2013-2018
  • Figure 4-5: Australia - NIPT Market (Volume ‘000), 2013-2018
  • Figure 4-6: China - Number of Births (Million), 2013-2018
  • Figure 4-7: China - Potential Market in Two Different Scenarios (US$), 2012
  • Figure 4-8: China - NIPT Market (Million US$), 2013-2018
  • Figure 4-9: China - NIPT Market (Volume ‘000), 2013-2018
  • Figure 4-10: Japan - Number of Births (‘000), 2013-2018
  • Figure 4-11: Japan - Number of Births by Mother's Risk of Down's syndrome (%), 2010
  • Figure 4-12: Japan - Potential Market in Two Different Scenarios (US$), 2013
  • Figure 4-13: Japan - NIPT Market (Million US$), 2013-2018
  • Figure 4-14: Japan - NIPT Market (Volume ‘00), 2013-2018
  • Figure 4-15: India - Number of Births (Million), 2013-2018

List of Tables:

  • Table 3-1: Comparison of Features of Key NIPT Tests in APAC NIPT Market
  • Table 3-2: MaterniT21 PLUS Test Validation Results
  • Table 3-3: Verifi Test Validation Results
  • Table 3-4: Panorma Test Validation Results
  • Table 3-5: Harmony Test Validation Results
  • Table 3-6: NIFTY Test - Summary of Phase I Clinical Trial
  • Table 3-7: NIFTY Test - Summary of Phase II Clinical Trial
  • Table 3-8: Bambni Test - Summary of Phase I Clinical Trial
  • Table 3-9: Bambni Test - Summary of Phase II Clinical Trial
  • Table 3-10: Risk of Down's syndrome with Rise in Maternal Age
  • Table 4-1: Australia - Number of Births by Age of Mother (2011)
  • Table 4-2: Australia NIPT Market Landscape - Players; Australian Partner; Cost per Test
  • Table 4-3: China NIPT Market Landscape - Players; Cost per Test
  • Table 4-4: Japan - Number of Births by Age of Mother (2010)
  • Table 4-5: Japan NIPT Market Landscape - Player; Cost per Test
Back to Top